Acasti Pharma Inc. Proxy Statement: Your Vote Matters!

TL;DR

Acasti Pharma DEFA14A filed 9/6/24 - VOTE NOW, YOUR VOICE COUNTS!

AI Summary

Acasti Pharma Inc. filed a Definitive Additional Materials (DEFA14A) on September 6, 2024, related to its Annual and Special Meeting of Shareholders. The filing serves as a proxy statement, reminding shareholders that their vote matters and encouraging them to vote today. The company is incorporated in A8 and has a fiscal year end of March 31.

Why It Matters

This filing is important for shareholders as it contains information and prompts them to participate in the company's Annual and Special Meeting, influencing corporate governance and decisions.

Risk Assessment

Risk Level: low — This filing is a standard proxy statement and does not contain information that suggests immediate or significant financial risk.

Key Players & Entities

• Acasti Pharma Inc. (company) — Registrant and filer of the proxy statement
• 0001140361-24-040463 (filing_id) — Accession number for the SEC filing
• September 6, 2024 (date) — Date of filing and communication to shareholders
• 103 Carnegie Center, Suite 300, Princeton, NJ 08540 (address) — Business and mailing address of Acasti Pharma Inc.

FAQ

Filing Documents

• ef20035567_defa14a.htm (DEFA14A) — 13KB
• image00001.jpg (GRAPHIC) — 3KB
• 0001140361-24-040463.txt ( ) — 19KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a 12 ACASTI PHARMA INC. (Name of Registrant as Specified in its Charter) Not Applicable (Name of Person(s) Filing Proxy Statement if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. YOUR VOTE MATTERS PLEASE VOTE TODAY September 6, 2024 Dear Shareholder: The Annual and Special Meeting of Shareholders of Acasti Pharma Inc. (NASDAQ: ACST) scheduled to be held on September 30, 2024 is rapidly approaching. Our recent records show that you have not yet voted your shares. Your vote is very important. Please take one moment of your time to participate in this year's meeting by voting your proxy today. Internet and telephone voting are available for your convenience and represent the most prompt methods to record your vote. Please follow the instructions on the proxy card or voting instruction form sent to you in order to review the Proxy Statement/Prospectus and to vote on these important matters. The Board recommends a vote: "FOR" the election of each of the director nominees named in the Proxy Statement/Prospectus to serve until the close of the next annual meeting of Shareholders or until his successor is elected or appointed. "FOR" the appointment of KPMG LLP as our independent registered public accounting firm until the close of the next annual meeting of Shareholders and to authorize the Board to fix such independent registered public accounting firm's remuneration. "FOR" the advisory (non-binding) resolution approving the compensation of our named executive officers, as disclosed in the Proxy Statement/Prospectus. "FOR" the Continuance Resolution approving the Continuance, as disclosed in the Proxy Statement/Prospectus. "FOR" the Domestication Resolution approving the Domestication and the certificate of incorporation governing Acasti post-Domestication, as disclosed in the Proxy "FOR" the approval of the 2024 Equity Incentive Plan, as disclosed in the Proxy Statement/Prospectus. Please vote your shares today. If you need assistance voting your shares, please contact D.F. King & Co., Inc., our proxy solicitor, toll free at (800) 488-8035. On behalf of your Board of Directors, thank you for your participation and continued support. Sincerely, /s/ Prashant Kohli Prashant Kohli Chief Executive Officer

View Full Filing

View this DEFA14A filing on SEC EDGAR